Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein
- PMID: 7128006
- DOI: 10.1038/clpt.1982.217
Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein
Abstract
Because of their elevated concentrations of plasma alpha 1-acid glycoprotein (AAG), cancer patients had a lower free fraction of methadone in plasma than did members of a control group. This difference was not great (-20%), but there was a fourfold variation in free fraction among a group of 13 patients (0.064 to 0.23). The bound/free methadone concentration ratio correlated linearly with plasma AAG. The binding of methadone to AAG was characterized by two classes of binding sites, the more avid having an association constant of 4 X 10(5)M-1 and an N of 0.38. Methadone could be displaced from AAG binding sites by a number of drugs: propranolol, chlorpromazine, prochlorperazine, thioridazine, and imipramine. The concentrations required for significant displacement (27 microM), as well as the relatively low Ka for methadone, suggest that the free fraction of methadone will not be significantly affected by elevated methadone concentrations or through displacement by other drugs that also bind to AAG.
Similar articles
-
Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein.Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004. Pharmacogenetics. 1996. PMID: 8946472
-
Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein.Clin Pharmacol Ther. 1990 Mar;47(3):338-46. doi: 10.1038/clpt.1990.37. Clin Pharmacol Ther. 1990. PMID: 2311335
-
Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding.Clin Pharmacol Ther. 1982 Nov;32(5):659-63. doi: 10.1038/clpt.1982.218. Clin Pharmacol Ther. 1982. PMID: 7128007
-
Human alpha-1-glycoprotein and its interactions with drugs.Drug Metab Rev. 2001 May;33(2):161-235. doi: 10.1081/dmr-100104402. Drug Metab Rev. 2001. PMID: 11495502 Review.
-
Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.Curr Drug Metab. 2013 Feb;14(2):226-38. Curr Drug Metab. 2013. PMID: 23092311 Review.
Cited by
-
Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein.Br J Clin Pharmacol. 1993 Sep;36(3):241-9. doi: 10.1111/j.1365-2125.1993.tb04224.x. Br J Clin Pharmacol. 1993. PMID: 9114911 Free PMC article.
-
Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.Naunyn Schmiedebergs Arch Pharmacol. 1988 Feb;337(2):220-4. doi: 10.1007/BF00169251. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3368020
-
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003. Clin Pharmacokinet. 2002. PMID: 12405865 Review.
-
Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.Cancer Chemother Pharmacol. 1994;35(2):101-8. doi: 10.1007/BF00686630. Cancer Chemother Pharmacol. 1994. PMID: 7987984 Clinical Trial.
-
Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.Br J Clin Pharmacol. 2000 Nov;50(5):427-40. doi: 10.1046/j.1365-2125.2000.00272.x. Br J Clin Pharmacol. 2000. PMID: 11069437 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources